(Q36307839)

13 August 2017

1 reference

title

Selegiline orally disintegrating tablets for the treatment of Parkinson's disease (English)

1 reference

13 August 2017

1 reference

Mark F Lew

1

1 reference

13 August 2017

publication date

1 November 2005

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

13 August 2017

published in

1 reference

13 August 2017

volume

5

1 reference

13 August 2017

issue

6

1 reference

13 August 2017

page(s)

705-712

1 reference

Neuronal pathology in Parkinson's disease

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.705

Levodopa in the treatment of Parkinson's disease: current controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.705

On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.705

Impact of the motor complications of Parkinson's disease on the quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.705

Discontinuing antiepileptic drugs in patients who are seizure free on monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.705

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.705

Parkinson's disease. Second of two parts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.705

Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.705

Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.705

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.705

Clinical pharmacokinetics and pharmacodynamics of selegiline. An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.705

Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.705

A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.705

A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.705

Severe adverse interaction between pethidine and selegiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.705

Safety of selegiline (deprenyl) in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.705

21 January 2018

Identifiers

DOI

10.1586/14737175.5.6.705

1 reference

13 August 2017

1 reference